Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)

European Heart Journal

Volumn 17, Issue SUPPL. F, 1996, Pages 37-42

  De Faire, U ^a   Ericsson, C G ^a   Grip, L ^a   Nilsson, J ^a   Svane, B ^a   Hamsten, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bezafibrate; Coronary angiography; Coronary atherosclerosis; Dyslipidaemia; Triglyceride rich lipoproteins

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CHOLESTEROL; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESIN; STATIN; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ATHEROMA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FIBRINOGEN BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029845294     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/17.suppl_f.37     Document Type: Conference Paper

References (0)